The Global Aortic Stenosis Market Growth Accelerated by Increasing Geriatric Population
Aortic stenosis is a common heart valve disease caused by the narrowing of the aortic valve opening, restricting blood flow from the heart into the main artery. Left untreated, it can cause serious complications and lead to death. Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are the primary treatment options that help in restoring normal blood flow. TAVR valves provide a less invasive treatment option specifically for high-risk patients who cannot undergo open-heart surgery.
Market key trends:
The growth of the aortic stenosis market is majorly driven by the increasing geriatric population worldwide who are more prone to develop heart valve disorders. As per WHO, by 2050 over 2 billion people will be aged over 60 years presenting a huge patient pool. Additionally, sedentary lifestyle and prevalence of obesity leading to risk factors like hypertension and diabetes have contributed to the rising incidence of aortic stenosis. Technological advancements in TAVR valves bringing in miniaturized, repositionable valves along with MRI compatibility has expanded treatment eligibility. This has further augmented the adoption rate of TAVR procedures over surgical replacement.
Segment Analysis
The global aortic stenosis market is segmented into various categories such as type, treatment, and end-user. Based on type, the market is categorized into congenital and acquired. The acquired segment is dominating the market due to the growing prevalence of aging and obese population. Based on treatment, the market is classified into medical management, balloon aortic valvuloplasty, and aortic valve replacement. The aortic valve replacement segment dominates the market as it the preferred treatment for severe aortic stenosis cases. Based on end-user, the market is divided into hospitals, specialty clinics, and ambulatory surgical centers. Hospitals dominates the market as aortic stenosis surgeries are mostly performed in hospitals.
Key Takeaways
The global aortic stenosis market is expected to witness high growth. The market size is projected to grow from US$ 8.33 Billion in 2023 to US$ 16.66 Billion by 2030, at a CAGR of 10%.
Regional analysis
North America dominates the regional market owing to increasing prevalence of cardiovascular diseases and developed healthcare infrastructure. According to the American Heart Association, by 2030, more than 130 million Americans will be diagnosed with some form of cardiovascular disease. Asia Pacific is expected to witness fastest growth during the forecast period due to large patient pool, increasing healthcare expenditure, and rising focus towards cardiac diseases.
Key players
Key players operating in the aortic stenosis market are Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, CryoLife, Inc., Braile Biomédica, JenaValve Technology, Inc., Meril Life Sciences Pvt. Ltd., Micro Interventional Devices, Inc., and egnite, Inc. Edwards Lifesciences Corporation dominates the market owing to strong product portfolio and international presence.
Comments
Post a Comment